Joel Beatty Analyst PerformanceBiotechnology Equity Research Analyst at Robert W. BairdJoel Beatty is a stock analyst at Robert W. Baird focused in the medical sector, covering 37 publicly traded companies. Over the past year, Joel Beatty has issued 22 stock ratings, including buy and hold recommendations. While full access to Joel Beatty's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Joel Beatty's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings93 Last 10 YearsBuy Recommendations77.01% 67 Buy RatingsCompanies Covered37 Unique Companies Ratings Distribution87RatingsDistribution of strong buy, buy, hold, and sell ratings by Joel Beatty.RatingPercentageCount Strong Buy0.0%0 ratings Buy77.0%67 ratings Hold21.8%19 ratings Sell1.1%1 ratingsOut of 87 total stock ratings issued by Joel Beatty at Robert W. Baird, the majority (77.0%) have been Buy recommendations, followed by 21.8% Hold and 1.1% Sell.Best & Worst CallsBest Call0000.0%PRAXMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%TPSTMar 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ97.3% of companies on NASDAQ36 companiesNYSE2.7% of companies on NYSE1 companyJoel Beatty, an analyst at Robert W. Baird, currently covers 37 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical36 companies97.3%Consumer Staples1 company2.7%Joel Beatty of Robert W. Baird specializes in stock coverage within the Medical sector, with additional focus on Consumer Staples companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE28 companies75.7%MED - DRUGS6 companies16.2%BIOTECHNOLOGY2 companies5.4%COSMETICS&TLTRS1 company2.7% Joel Beatty's Ratings History at Robert W. Baird Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsALKSAlkermes5/13/2026Boost Price Target$38.29$48.00Outperform$0.0000.00% ROIAXSMAxsome Therapeutics5/5/2026Boost Price Target$224.03$246.00Outperform$0.0000.00% ROIELFe.l.f. Beauty4/28/2026Lower Price Target$63.73$90.00Outperform$0.0000.00% ROIDNLIDenali Therapeutics4/7/2026Boost Price Target$19.38$34.00Outperform$0.0000.00% ROIDNLIDenali Therapeutics3/26/2026Boost Price Target$22.47$32.00Outperform$0.0000.00% ROIIMMPPrima BioMed3/13/2026Downgrade$2.76$1.00Neutral$0.0000.00% ROIDNTHDianthus Therapeutics3/10/2026Boost Price Target$79.23$132.00Outperform$0.0000.00% ROICTNMContineum Therapeutics3/6/2026Boost Price Target$13.81$20.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines2/20/2026Set Price Target$331.61$433.00Outperform$0.0000.00% ROIELFe.l.f. Beauty2/5/2026Set Price Target$84.55$115.00$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. RAREUltragenyx Pharmaceutical12/30/2025Lower Price Target$22.28$47.00Outperform$0.0000.00% ROICTNMContineum Therapeutics11/24/2025Lower Price Target$10.67$14.00Outperform$0.0000.00% ROIJAZZJazz Pharmaceuticals11/18/2025Boost Price Target$173.98$209.00Outperform$0.0000.00% ROIELFe.l.f. Beauty11/6/2025Lower Price Target$76.28$125.00Outperform$0.0000.00% ROIAMLXAmylyx Pharmaceuticals10/16/2025Boost Price Target$15.79$19.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics9/30/2025Lower Price Target$3.38$7.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics9/9/2025Boost Price Target$31.80$67.00Outperform$0.0000.00% ROIEDITEditas Medicine8/13/2025Boost Price Target$2.29$6.00Outperform$0.0000.00% ROIPTCTPTC Therapeutics8/8/2025Set Price Target$45.38$70.00$0.0000.00% ROICOGTCogent Biosciences7/8/2025Boost Price Target$9.35$9.00Neutral$0.0000.00% ROISAGESage Therapeutics6/20/2025Boost Price Target$9.15$9.00Neutral$0.0000.00% ROIELFe.l.f. Beauty6/6/2025Boost Price Target$118.65$145.00Outperform$0.0000.00% ROIACADACADIA Pharmaceuticals5/19/2025Boost Price Target$21.76$31.00Outperform$00.0000.00% ROIELFe.l.f. Beauty5/14/2025Boost Price Target$78.35$100.00Outperform$00.0000.00% ROIEDITEditas Medicine5/13/2025Lower Price Target$1.54$4.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics5/13/2025Lower Price Target$20.08$50.00Outperform$00.0000.00% ROIDNLIDenali Therapeutics5/8/2025Lower Price Target$14.26$29.00Outperform$00.0000.00% ROIPTCTPTC Therapeutics5/7/2025Lower Price Target$40.26$66.00Outperform$00.0000.00% ROIJAZZJazz Pharmaceuticals5/7/2025Lower Price Target$102.22$155.00Outperform$000.0000.00% ROICOGTCogent Biosciences5/7/2025Lower Price Target$4.74$7.00Neutral$00.0000.00% ROIAXSMAxsome Therapeutics5/6/2025Boost Price Target$116.49$162.00Outperform$000.0000.00% ROIALKSAlkermes5/2/2025Boost Price Target$30.58$41.00Outperform$00.0000.00% ROINGNENeurogene3/25/2025Set Price Target$8.20$38.00$00.0000.00% ROILRMRLarimar Therapeutics3/25/2025Lower Price Target$2.28$10.00Outperform$0.0000.00% ROIDFTXDefinium Therapeutics3/7/2025Lower Price Target$6.61$16.00Outperform$00.0000.00% ROICTNMContineum Therapeutics3/7/2025Lower Price Target$6.44$16.00Outperform$00.0000.00% ROIARGXargenex3/4/2025Boost Price Target$631.50$680.00Neutral$000.0000.00% ROIPRAXPraxis Precision Medicines3/3/2025Lower Price Target$38.60$73.00Outperform$000.0000.00% ROICPRXCatalyst Pharmaceuticals3/3/2025Boost Price Target$22.89$32.00Outperform$00.0000.00% ROIAXSMAxsome Therapeutics3/3/2025Boost Price Target$127.54$160.00Outperform$000.0000.00% ROIThe chokepoint supplier behind SpaceX's $1.75 trillion empire (Ad)When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.See the stock Musk's own words pointed to right hereCOGTCogent Biosciences2/27/2025Lower Price Target$6.71$8.00Neutral$00.0000.00% ROICPRXCatalyst Pharmaceuticals2/4/2025Initiated Coverage$22.62$28.00Outperform$00.0000.00% ROIAXSMAxsome Therapeutics2/3/2025Set Price Target$137.75$132.00$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James FinancialBMO Capital Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
